Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;24(8):669-93.
doi: 10.2165/11533230-000000000-00000.

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

John H Krystal  1 , Sanjay J Mathew, D Cyril D'Souza, Amir Garakani, Handan Gunduz-Bruce, Dennis S Charney
Affiliations
Review

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

John H Krystal et al. CNS Drugs. 2010 Aug.

Abstract

Drugs acting at metabotropic glutamate receptors (mGluRs) are among the most promising agents under development for the treatment of psychiatric disorders. The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the treatment of any psychiatric disorder. However, in the areas of schizophrenia, anxiety disorders and mood disorders, research conducted in animal models appears to translate well into efficacy in human laboratory-based models of psychopathology and in preliminary clinical trials. Further, the genes coding for mGluRs are implicated in the risk for a growing number of psychiatric disorders. This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials. It describes the potential value of mGluR2 and mGluR5 agonists and positive allosteric modulators for the treatment of schizophrenia. It also reviews evidence that group II mGluR agonists and positive allosteric modulators as well as group I mGluR antagonists might also treat anxiety disorders and some forms of depression, while mGluR2 and group I mGluR antagonists (particularly mGluR5 antagonists) might have antidepressant properties. This review also links growing insights into the role of glutamate in the pathophysiology of these disorders to hypothesized mGluR-related treatment mechanisms.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Neurosci. 2002 May;5(5):405-14 - PubMed
    1. J Neurophysiol. 2005 Apr;93(4):1989-2001 - PubMed
    1. Neuropharmacology. 1999 Oct;38(10):1597-606 - PubMed
    1. Biol Psychiatry. 2007 Oct 1;62(7):739-46 - PubMed
    1. Neuropharmacology. 1999 Dec;38(12):1831-9 - PubMed

Publication types

MeSH terms

Substances